Chronic inflammation, immune cell trafficking and anti-trafficking agents
10:00 AM PDT / 1:00 PM EDT / 6:00 PM BST / 7:00 PM CEST
Inflammatory bowel diseases (IBDs) are characterized by uncontrolled activation of intestinal immune cells in a genetically susceptible host (reviewed in Nat Immunol. 2019 Aug;20(8):970-979). Studies have identified altered trafficking of immune cells and pathogenic immune cell circuits as crucial pathways for mucosal inflammation and tissue destruction in IBD. Two major factors, namely a defective gut barrier and microbial dysbiosis, favour mucosal inflammation and lead to accumulation and local activation of immune cells.
There are many novel therapeutic approaches targeting cytokines or cytokine signaling events in IBD. For instance, studies in recent years have identified a pivotal role of the cytokine IL-23 in the pathogenesis of IBD. Genetic studies revealed that subgroups of IBD patients have single nucleotide polymorphisms in the IL-23R gene suggesting that IL-23R signaling affects disease susceptibility. Moreover, in several murine models of colitis, suppression of IL-12/IL-23 p40, IL-23 p19 or IL-23R function led to marked suppression of gut inflammation. This finding was associated with reduced activation of IL-23 target cells such as T helper 17 cells, innate lymphoid cells type 3, granulocytes and natural killer cells as well as with impaired production of proinflammatory cytokines.
The webinar will focus on IL-23, which is emerging as an important concept in suppressing gut inflammation and inflammation-related cancer growth.
Prof. Dr. Markus F. Neurath is a well-known Medical Gastroenterologist with experience of more than 30+ years in the field.
He studied medicine at the Phillips University of Marburg from 1984 to 1990, and later worked as an intern at the 1st Medical Clinic and Polyclinic of Johannes Gutenberg University of Mainz, where he received his doctorate in 1990. In 1997, he completed his specialist degree in internal medicine, completed his habilitation in 1998, and was then a senior physician. In 1999, he was a visiting professor at the Clinic for Gastroenterology at Brigham and Woman's Hospital and Harvard Medical School on a Fulbright Fellowship in Boston.
Since 2009, he has been Director of Medical Clinic 1 at the University Hospital Erlangen.
He received the Theodor Frerichs Prize and the Thannhauser Prize of the German Society for Gastroenterology. In 2005, he received the Dr. Norbert Henning Prize from the University of Erlangen and in 2006 the Ernst Jung Prize.
He has a special interest in hepatology (liver disease), gastroenterology (diseases of the digestive organs), intensive care, hepatobiliary, gastrointestinal & neuroendocrine tumor diseases, diagnostic, and interventional endoscopy.
Dr. Neurath has written various articles and publications in state and national medical journals.